
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc., a clinical-stage biotechnology company, is making significant strides with its lead product candidate, ADI-001, demonstrating strong efficacy in treating both lupus nephritis and systemic lupus erythematosus, which may bolster its market position in the autoimmune sector. The anticipated initiation of a Phase 1 study for ADI-212 targeting metastatic castration-resistant prostate cancer in 2026 indicates further expansion into oncology, adding potential high-value milestones to the company's pipeline. Additionally, Adicet’s strategy to partner with third-party manufacturers for commercial-scale production mitigates manufacturing risks, enhancing operational efficiency and positioning the company favorably for future growth opportunities.
Bears say
Adicet Bio Inc is projected to incur a net loss of $1.13 per share by 2025, raising concerns about its financial sustainability as it navigates a challenging clinical development landscape. Key risks include potential negative clinical data, slower-than-expected progress in clinical trials, and increased regulatory hurdles, particularly as no gamma-delta T-cell therapies have received FDA approval to date. Furthermore, the reduction in the probability of success for its candidate ADI-001 in certain autoimmune conditions to 15%, coupled with heightened competition, suggests a potential for diminished market share and revenue, contributing to a negative outlook on the company's financial future.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares